| P2093 | author name string | Ying Zhang | |
| | Roger Abounader | |
| | David Schiff | |
| | Fadila Guessous | |
| | Alex Kofman | |
| P2860 | cites work | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis | Q24683896 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Signal transduction via the stem cell factor receptor/c-Kit | Q28291675 |
| | Lung cancer | Q29615473 |
| | Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 |
| | Malignant gliomas in adults | Q29615708 |
| | Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities | Q30319080 |
| | Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. | Q35669147 |
| | Intracellular signal transduction pathway proteins as targets for cancer therapy. | Q36177026 |
| | Targeting VEGF in cancer therapy | Q36380193 |
| | Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents | Q36395924 |
| | Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. | Q36613519 |
| | FLT3 mutations: biology and treatment | Q36662153 |
| | Medullary thyroid cancer: therapeutic targets and molecular markers | Q36667663 |
| | Dysregulated RET signaling in thyroid cancer. | Q37172765 |
| | MET as a target for treatment of chest tumors | Q37232416 |
| | Inhibitors of vascular endothelial growth factor in cancer | Q37294225 |
| | Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor | Q37408097 |
| | Angiogenesis in the treatment of non-small cell lung cancer | Q37435385 |
| | Emerging therapeutic targets in non-small cell lung cancer | Q37435391 |
| | Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | Q37435425 |
| | Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 |
| | Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. | Q40751631 |
| | Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells | Q41071769 |
| | Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth | Q41103718 |
| | Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas | Q42038344 |
| | Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function | Q43149105 |
| | Prognostic significance of c-Met expression in glioblastomas | Q46170165 |
| | Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. | Q47955121 |
| | In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis | Q48700301 |
| | Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. | Q48789795 |
| | Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression | Q73004517 |
| | Medullary thyroid carcinoma | Q80541075 |
| | Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy | Q80914233 |
| | Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms | Q83588875 |
| P433 | issue | 2 | |
| P921 | main subject | glioblastoma | Q282142 |
| | cabozantinib | Q795057 |
| | thyroid cancer | Q826522 |
| P304 | page(s) | 112-121 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | IDrugs: the Investigational Drugs Journal | Q15752554 |
| P1476 | title | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC | |
| P478 | volume | 13 | |